Insights

Strategic Growth Acquisition of PhenoVista Biosciences and DOPPL/Sun Bioscience signals rapid expansion in imaging, phenotypic assays, and organoid technologies, presenting upsell opportunities for integrated high-content screening and advanced analytics services.

Executive Focus Promotion of Olivier Frey to COO/CTO and emphasis on technology strategy, digitalization, and automation indicate a continued push toward scalable platforms, offering cross-sell of automated workflows, data management, and AI-driven decision support.

Platform Expansion New DIGIT platform launch plus ongoing Liver, Islet Biology, Oncology & Immunology focus create multiple entry points for custom 3D in vitro models, enabling tailored services for pharma and biotech pipelines seeking safety and efficacy screening.

Strategic Partnerships Recent collaboration with PharmaNest for machine learning on human pre-clinical models highlights a opportunity to propose joint ventures, data licensing, and co-development projects combining organ models with ML analytics.

Geographic & Market Position Switzerland-based leadership with global acquisitions positions InSphero as a comprehensive 3D model provider; target international customers in pharma, especially mid-to-large firms seeking robust, high-throughput safety and efficacy platforms.

Similar companies to InSphero

InSphero Tech Stack

InSphero uses 8 technology products and services including Linkedin Insight Tag, Microsoft Clarity, Joomla, and more. Explore InSphero's tech stack below.

Media & News

InSphero's Email Address Formats

InSphero uses at least 4 email formats:
InSphero Email FormatsExamplePercentage
First.Last@insphero.comJohn.Doe@insphero.com
95%
First.Middle@insphero.comJohn.Michael@insphero.com
3%
FirstMiddle.Last@insphero.comJohnMichael.Doe@insphero.com
1%
FirstLast@insphero.comJohnDoe@insphero.com
1%

Frequently Asked Questions

What is InSphero's phone number?

Minus sign iconPlus sign icon
You can contact InSphero's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is InSphero's official website and social media links?

Minus sign iconPlus sign icon
InSphero's official website is insphero.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does InSphero generate?

Minus sign iconPlus sign icon
As of October 2026, InSphero's annual revenue is estimated to be $1M - $10M.

What is InSphero's SIC code and NAICS code?

Minus sign iconPlus sign icon
InSphero's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does InSphero have currently?

Minus sign iconPlus sign icon
As of October 2026, InSphero has approximately 82 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer And Board Member: J. L., Chief Business Officer: P. E. C. and Chief Scientific Officer: M. L. N. Explore InSphero's employee directory with LeadIQ.

What industry does InSphero belong to?

Minus sign iconPlus sign icon
InSphero operates in the Biotechnology Research industry.

What technology does InSphero use?

Minus sign iconPlus sign icon
InSphero's tech stack includes Linkedin Insight Tag, Microsoft Clarity, Joomla, WordPress, Microsoft 365, LiveChat, HubSpot and Wistia.

What is InSphero's email format?

Minus sign iconPlus sign icon
InSphero's email format typically follows the pattern of First.Last@insphero.com. Find more InSphero email formats with LeadIQ.

How much funding has InSphero raised to date?

Minus sign iconPlus sign icon
As of October 2026, InSphero has raised $35M in funding. The last funding round occurred on Mar 31, 2023.

When was InSphero founded?

Minus sign iconPlus sign icon
InSphero was founded in 2009.
InSphero logo

InSphero

Biotechnology ResearchZurich, Switzerland51-200 Employees

InSphero is a biotechnology research company based at 27a Wagistrasse, Schlieren, Zurich 8952, Switzerland, with 51-200 employees. The company develops 3D in vitro spheroid-based models and related platforms to support drug safety and efficacy testing. Its product areas cover liver safety, liver disease, islet biology, and oncology and immunology. InSphero has pursued growth through acquisitions and partnerships, including the 2026 acquisition of PhenoVista Biosciences and the 2025 acquisitions of Doppl SA and Sunbioscience, as well as a 2026 partnership with PharmaNest. In 2026, InSphero launched the 3D InSight Drug-Induced Gastrointestinal Toxicity platform, reflecting ongoing platform evolution.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $35M

    InSphero has raised a total of $35M of funding over 9 rounds. Their latest funding round was raised on Mar 31, 2023 as a Venture Round.

  • $1M - $10M

    InSphero's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.